Physician profile
Weijing Sun
NPI 1811925316
$150,275.20
in general payments reported to CMS, 2019-2025
21 companies · $33K in 2025
The $33K reported for 2025 was more than what 92% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $1,593 · 2021: $2,186 · 2022: $17K · 2023: $33K · 2024: $38K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Travel and Lodging: $15K · Consulting Fee: $5,105 · Food and Beverage: $3,728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,875.00 |
| Travel and Lodging | $15,029.99 |
| Consulting Fee | $5,105.00 |
| Food and Beverage | $3,727.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $49,719.66 | 2024-2025 | Onivyde |
| Astellas Pharma US INC | $40,333.87 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $25,454.93 | 2019-2025 | Keytruda |
| Taiho Oncology, INC. | $11,459.95 | 2019 | |
| Agios Pharmaceuticals, INC. | $3,806.92 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $3,651.81 | 2022-2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $2,641.84 | 2019 | |
| Beone Medicines USA, INC. | $2,630.59 | 2025 | Tevimbra |
| Eisai INC. | $2,472.58 | 2019-2021 | |
| Gilead Sciences, INC. | $2,180.00 | 2025 | |
| Astrazeneca Uk Limited | $2,055.00 | 2021 | |
| Daiichi Sankyo INC. | $1,578.66 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $1,573.49 | 2024-2025 | |
| Beigene USA, INC. | $274.26 | 2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $161.45 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $139.71 | 2022 | |
| Genentech, INC. | $88.08 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $52.40 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weijing Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.